Cell Source, Inc. (CLCS) Stock

About Cell Source, Inc.

Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.

Cell Source, Inc. is headquartered in US.

Cell Source, Inc. (CLCS) stock trades at $0.80 with a market capitalization of $36.03M. The stock is valued at a price-to-earnings (P/E) ratio of -8.00, price-to-book of -1.94, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.30 and $2.25, and currently trades 64.4% below its 52-week high.

On profitability, Cell Source, Inc. generates a return on equity (ROE) of 22.48% — well above the market average, a sign of a high-quality business, return on capital employed of 12.13%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cell-source.com